Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC) von Stanton, Sasha E., MacDonald, Lisa Diana, Mellinger, Staci L., Moxon, Nicole, Kelly, Tracy, Hirsch, Heather Anne, Fiset, Stephan, Young, Kristina Hoot, Page, David B.

Volltext

A phase II trial of TGFβ type I receptor inhibitor, galunisertib, plus neoadjuvant chemoradiation in patients with locally advanced rectal cancer von Young, Kristina Hoot, Gunderson, Andrew J, Gilchrist, Miranda, Whiteford, Mark, Kiely, Maria X, Hayman, Amanda, O'Brien, David P, Ahmad, Rehan, Manchio, Jeffrey V, Brosnan, Evelyn, Vaccaro, Gina M., Li, Rui, Simon, Miklos, McCormick, Mary, Drokin, Ashley, Cramer, Julie, Urba, Walter John, Gough, Michael, Crittenden, Marka R., Yamazaki, Tomoko

Volltext

Preclinical combination of radiation and fibroblast activation protein inhibition in pancreatic cancer von Young, Kristina Hoot, McCarty, Kayla, Friedman, David, Cottam, Benjamin, Newell, Pippa, Gough, Michael, Crittenden, Marka R.

Volltext